• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A fine addition: Finerenone in the evolving landscape of heart failure with preserved ejection fraction.

作者信息

Halaseh Rami, Sauer Andrew J, Vardeny Orly, Canonico Mario Enrico, Harrington Josephine, Svetlichnaya Jana, Ambrosy Andrew P

机构信息

Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.

出版信息

Heart Fail Rev. 2025 Mar;30(2):287-291. doi: 10.1007/s10741-024-10462-2. Epub 2024 Oct 30.

DOI:10.1007/s10741-024-10462-2
PMID:39476221
Abstract
摘要

相似文献

1
A fine addition: Finerenone in the evolving landscape of heart failure with preserved ejection fraction.一项出色的补充：非奈利酮在射血分数保留的心力衰竭不断演变的格局中的作用
Heart Fail Rev. 2025 Mar;30(2):287-291. doi: 10.1007/s10741-024-10462-2. Epub 2024 Oct 30.
2
[Mineralocorticoid receptor antagonists in heart failure with preserved/mildly reduced ejection fraction: from TOPCAT to FINEARTS-HF].[射血分数保留/轻度降低的心力衰竭中的盐皮质激素受体拮抗剂：从TOPCAT研究到FINEARTS-HF研究]
G Ital Cardiol (Rome). 2025 Jan;26(1):38-49. doi: 10.1714/4394.43958.
3
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.非奈利酮对射血分数保留的心力衰竭/射血分数轻度降低的心力衰竭患者KCCQ的影响：FINEARTS-HF的预先设定分析
J Am Coll Cardiol. 2025 Jan 21;85(2):120-136. doi: 10.1016/j.jacc.2024.09.023. Epub 2024 Sep 29.
4
Focus on finerenone: the FINEARTS-HF study.聚焦非奈利酮：FINEARTS-HF研究。
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii156-iii161. doi: 10.1093/eurheartjsupp/suaf035. eCollection 2025 Mar.
5
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.射血分数保留、轻度降低与降低的心衰患者的全面特征分析——来自 ESC-HFA EORP 心衰长期注册登记研究的结果
Eur J Heart Fail. 2022 Feb;24(2):335-350. doi: 10.1002/ejhf.2408. Epub 2022 Jan 10.
6
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.非甾体类盐皮质激素受体拮抗剂非奈利酮与射血分数保留的心力衰竭。
Cardiovasc Diabetol. 2023 Jun 29;22(1):162. doi: 10.1186/s12933-023-01899-0.
7
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial.射血分数轻度降低或保留的心衰患者的基线特征：FINEARTS-HF 试验。
Eur J Heart Fail. 2024 Jun;26(6):1334-1346. doi: 10.1002/ejhf.3266. Epub 2024 May 11.
8
Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.N 端脑利钠肽前体在射血分数保留型、中间范围型和降低型心力衰竭中的相关性及其预后和鉴别诊断作用。
J Card Fail. 2018 Jun;24(6):365-374. doi: 10.1016/j.cardfail.2018.03.010. Epub 2018 Mar 27.
9
Mild and moderate to severe early acute kidney injury following cardiac surgery among patients with heart failure and preserved vs. mid-range vs. reduced ejection fraction: A retrospective cohort study.心力衰竭患者且射血分数保留、中等范围及降低的情况下，心脏手术后发生轻度和中重度早期急性肾损伤：一项回顾性队列研究。
Eur J Anaesthesiol. 2022 Aug 1;39(8):673-684. doi: 10.1097/EJA.0000000000001713. Epub 2022 Jul 5.
10
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.心力衰竭中醛固酮受体拮抗剂的个体患者水平荟萃分析。
Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1.

本文引用的文献

1
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.左氧氟沙星在越南预防耐多药结核病中的应用
N Engl J Med. 2024 Dec 19;391(24):2304-2314. doi: 10.1056/NEJMoa2314325.
2
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.非奈利酮治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.
3
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1.
4
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
5
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.新型非甾体类盐皮质激素受体拮抗剂在心脏肾脏疾病中的应用
Br J Pharmacol. 2022 Jul;179(13):3220-3234. doi: 10.1111/bph.15747. Epub 2022 Jan 13.
6
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.非奈利酮治疗与高钾血症风险：来自 FIDELIO-DKD 试验的结果。
J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 3.
7
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.非甾体类盐皮质激素受体拮抗剂治疗心血管和肾脏疾病-联合治疗的新视角。
Pharmacol Res. 2021 Oct;172:105859. doi: 10.1016/j.phrs.2021.105859. Epub 2021 Aug 28.
8
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.在肾脏病和 2 型糖尿病患者中用非奈利酮发生的心血管事件。
N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
9
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
10
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.